Zhejiang Medicine H1 2026 Revenue RMB 4.386 Billion, Net Profit Falls 9.99%
Zhejiang Medicine disclosed its 2026 interim report on August 25. During the reporting period, the company achieved revenue of RMB 4.386 billion, up 1.46% year-on-year. Net profit attributable to shareholders of the listed company was RMB 606 million, down 9.99% year-on-year. Basic earnings per share stood at RMB 0.63.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is negative for Pharmaceuticals, with intensity 20/100 and 60% confidence over a short term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.